| Ytd | 94.93% | |
| 1y | 339.44% |
| Open | 10.13 | Prev Close | 10.13 | Low | 9.91 | High | 10.35 | Mkt Cap | 555.44M |
| Vol | 386.48K | Avg Vol | 1.83M | EPS | -0.91 | P/E | -11.22 | Forward P/E | -3.96 |
| Beta | 0.11 | Short Ratio | 2.94 | Inst. Own | 17.64% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 9.38 | 200-d Avg | 7.60 | 1yr Est | 7.00 |
IMMX News
NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
LOS ANGELES--(BUSINESS WIRE)---- $IMMX--IMMX Investors Have Opportunity to Join Immix Biopharma, Inc
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
LOS ANGELES, CA, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We
NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
Boston, Massachusetts--(Newsfile Corp. - July 23, 2026) - Block & Leviton is investigating Immix Bio
LOS ANGELES, July 21, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Immix Biopharma , (“ Imm
ATLANTA, July 20, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Immix Bioph
Philadelphia, Pennsylvania--(Newsfile Corp. - July 20, 2026) - Kehoe Law Firm, P.C. is investigating
BOSTON, July 20, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Immix Biopharma (Nasdaq:
https://www.statnews.com/2026/07/20/ronald-fischer-rhode-island-fugitive-richard-graydon-biotech/ As
Immix Biopharma (IMMX) might move higher on growing optimism about its earnings prospects, which is
BofA Securities initiates Immix Biopharma with Buy rating, citing NXC-201's potential in AL amyloido
The consensus price target hints at an 113.6% upside potential for Immix Biopharma (IMMX). While emp
Wall Street analysts updated ratings for CURB, INTU, ENGN. See their outlooks and targets at Benzing
Analysts changed outlook on top Wall Street names. See all changes on our analyst ratings page. Chec
The consensus price target hints at a 120.6% upside potential for Immix Biopharma (IMMX). While empi
- Financing includes leading U. S. biotechnology institutional investors and mutual funds - LOS ANGE
LOS ANGELES, May 21, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or
– Of first 20 patients, all four MRD-negative patients have converted to complete response (CR)
LOS ANGELES, CA, April 09, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “W
Shares of Immix Biopharma, Inc. (NASDAQ: IMMX - Get Free Report) have been given an average rating o
Wall Street analysts make changes to top stocks. Check our analyst ratings page for all updates. VAL
Wall Street analysts upgraded and initiated coverage on top stocks, including Redwire, Zions Bancorp
Top analysts change outlook on top names. See all analyst rating changes on Benzinga's analyst r
On Tuesday, 120 companies set new 52-week lows.
During Tuesday's session, 78 companies made new 52-week lows.
New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 12
During Wednesday's trading, 517 companies set new 52-week lows.
Wednesday's session saw 784 companies set new 52-week lows.
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week
On Monday, 721 companies achieved new lows for the year.
Tuesday's session saw 729 companies set new 52-week lows.
On Friday, 368 stocks hit new 52-week lows.
Wednesday's session saw 107 companies set new 52-week lows.
Gainers electroCore, Inc. (NASDAQ: ECOR) shares jumped 64% to settle at $0.88 on Wednesday after
Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday
Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares climbed 71.5% to $5.88.
Gainers Eargo, Inc. (NASDAQ: EAR) shares climbed 59.7% to close at $7.28 on Thurs after the comp